Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 3

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 3
---
 and/or held as cash or cash
items (including in demand deposit accounts).

Effecting Our Initial Business Combination

We are not presently engaged
in, and we will not engage in, any operations for an indefinite period of time following the IPO. We intend to effectuate our initial
business combination using cash from the proceeds of the IPO and the private placement of the Private Placement Units, the proceeds of
the sale of our shares in connection with our initial business combination, shares issued to the owners of the target, debt issued to
bank or other lenders or the owners of the target, or a combination of the foregoing.

While we may pursue an acquisition
opportunity in any industry or sector and in any region, we intend to focus on industries that complement our management team’s
background so we can capitalize on their ability to identify, acquire and support the operations of a successful business. Our initial
business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the
growth of a pharmaceutical business in the United States. Our focus will be on the pharmaceutical sector.

Business Strategy

Our acquisition and value
creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the
pharmaceutical industry. We believe our management team’s knowledge, decades of experience and relationships across this industry
can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within
the pharmaceutical industry. Our team is well positioned to originate attractive investment opportunities and has a history of executing
various business transactions in multiple geographies and under varying economic and financial market conditions.

Our team will identify potential
acquisition targets by leveraging existing relationships in combination with the market research data that aligns with the company’s
strategic goals and priorities. Market size, growth potential, competition, and barriers to entry are all essential factors to consider
as we identify the acquisition target. Our team intends to utilize an in-depth evaluation process of potential acquisition targets based
on financial performance, strategic fit, and potential synergies as well as the company’s products, and services to ensure our target
is aligned. Although the pharmaceutical industry is highly regulated, and there are many legal and regulatory considerations that companies
must consider, such as licensing requirements, export controls, and liability issues, we believe our sponsor’s expertise and track
record in the pharmaceutical space will help mitigate these factors by proactively advising potential target companies on navigating these
issues.

We believe that it